U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07213960) titled 'A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis' on Sept. 15.
Brief Summary: This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condi...